Drug Insights

User-friendly Guide to Find Oxycodone on Synapse

11 February 2024
2 min read

Oxycodone, a potent opioid analgesic, also referred to as a narcotic, is a medication used in the management of pain. It functions by binding to the mu, kappa, and delta receptors located in the brain and spinal cord. The elaborate chemical name of oxycodone is 4,5 α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one. Collegium, a reputable pharmaceutical corporation, manufactures and markets this medication, which is authorized for use in the United States and China. Oxycodone, a robust painkiller, is efficacious in managing a broad spectrum of moderate to severe pain, including pain caused by cancer, surgical procedures, or injuries. Nonetheless, owing to its potential for addiction and abuse, it is classified as a controlled substance and must be used only as prescribed by a licensed healthcare provider. Click on the image below to begin the exploration journey of Oxycodone through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Acepodia Gets US Approval for Innovative Anti-EGFR Cell Therapy Trial, ACE2016
Latest Hotspot
3 min read
Acepodia Gets US Approval for Innovative Anti-EGFR Cell Therapy Trial, ACE2016
11 February 2024
Acepodia Reveals US Regulatory Approval for Pioneering Anti-EGFR Allogeneic Cell Treatment Trial, Designated as ACE2016.
Read →
Harnessing Synapse for Diazepam Information: Strategies and Tips
Drug Insights
2 min read
Harnessing Synapse for Diazepam Information: Strategies and Tips
11 February 2024
Diazepam, a significant GABAA receptor agonist approved by Waylis in 1963, effectively treats conditions like muscle spasticity, alcohol withdrawal, anxiety disorders, and epilepsy.
Read →
EMA Accepts Submission for Linvoseltamab as Therapy for Recurrent/Resistant Multiple Myeloma
Latest Hotspot
3 min read
EMA Accepts Submission for Linvoseltamab as Therapy for Recurrent/Resistant Multiple Myeloma
11 February 2024
Regeneron Pharmaceuticals, Inc. revealed that the European Medicines Agency is reviewing their Marketing Authorization Application for the therapy, linvoseltamab.
Read →
Effortless Searching: How to Find Methylphenidate on Synapse
Drug Insights
2 min read
Effortless Searching: How to Find Methylphenidate on Synapse
11 February 2024
Methylphenidate hydrochloride is a leading CNS stimulant, first approved by the US on December 5, 1955, and developed by Novartis. It effectively treats narcolepsy, ADD, and ADHD.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.